GWM
RPRX icon

Geneos Wealth Management’s Royalty Pharma RPRX Stock Holding History

Geneos Wealth Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-104
Closed -$4.02K – 2551
2025
Q4 		$4.02K Buy
104
+65
+167% +$2.48K ﹤0.01% 2198
2025
Q3 		$1.38K Sell
39
-340
-90% -$12.3K ﹤0.01% 2370
2025
Q2 		$13.7K Buy
379
+12
+3% +$398 ﹤0.01% 2195
2025
Q1 		$11.4K Buy
367
+217
+145% +$6.88K ﹤0.01% 2203
2024
Q4 		$3.83K Sell
150
-12
-7% -$318 ﹤0.01% 2418
2024
Q3 		$4.58K Buy
+162
New +$4.49K ﹤0.01% 2095

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geneos Wealth Management's RPRX Position: Q1 2026 in Review

Geneos Wealth Management sold out of Royalty Pharma (RPRX) in Q1 2026, closing a stake of 104 shares — an estimated $4.02K sold.

Geneos Wealth Management first reported a position in RPRX in Q3 2024 and held it in 6 quarters. The position peaked at $13.7K in Q2 2025. 592 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Geneos Wealth Management reported no remaining Royalty Pharma position as of Q1 2026 after selling out during the quarter.
  • Geneos Wealth Management sold 104 Royalty Pharma shares in Q1 2026, an estimated $4.02K.
  • Geneos Wealth Management first reported a position in Royalty Pharma in Q3 2024 and held it in 6 quarters.
  • Geneos Wealth Management's Royalty Pharma position peaked at $13.7K in Q2 2025.
  • 592 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Geneos Wealth Management's 13F filing for Q1 2026, filed 5 May 2026.